Passage Bio Inc Cash Flow Conversion Efficiency
Passage Bio Inc cash flow conversion efficiency. Based on the latest financial reports, Passage Bio Inc (PASG) has a cash flow conversion efficiency ratio of -2.060x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.18 Million) by net assets ($4.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Passage Bio Inc (2018–2025)
Cash flow conversion efficiency of Passage Bio Inc from 2018 to 2025. This chart illustrates how Passage Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PASG stock price and chart for real-time trading data and today's change.
Passage Bio Inc Cash Flow Conversion Ratio Explained
Passage Bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Passage Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Passage Bio Inc ranked by their cash flow conversion efficiency. Also see PASG market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Compucom Software Limited
NSE:COMPUSOFT
|
0.008x |
|
Brimstone Investment Corporation Ltd
JSE:BRT
|
0.023x |
|
Kmi Wire And Cable Tbk
JK:KBLI
|
-0.009x |
|
Guideline Geo AB (publ)
ST:GGEO
|
0.072x |
|
Ihlas Ev Aletleri Imalat Sanayi ve Ticaret AS
IS:IHEVA
|
0.009x |
|
MedX Health Corp
V:MDX
|
0.069x |
|
Wong Engineering Corporation Bhd
KLSE:7050
|
-0.012x |
|
Kumulus Vape SA
PA:ALVAP
|
-0.027x |
Annual Cash Flow Conversion Efficiency for Passage Bio Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Passage Bio Inc from 2018 to 2025. Review Passage Bio Inc (PASG) financial flexibility to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.75 Million | $-31.51 Million | -1.680x | -114.61% |
| 2024-12-31 | $61.26 Million | $-47.96 Million | -0.783x | -11.31% |
| 2023-12-31 | $111.28 Million | $-78.26 Million | -0.703x | -19.80% |
| 2022-12-31 | $201.37 Million | $-118.21 Million | -0.587x | -47.44% |
| 2021-12-31 | $318.66 Million | $-126.88 Million | -0.398x | -50.68% |
| 2020-12-31 | $304.71 Million | $-80.52 Million | -0.264x | -15.48% |
| 2019-12-31 | $174.35 Million | $-39.90 Million | -0.229x | -115.00% |
| 2018-12-31 | $-12.17 Million | $-18.57 Million | 1.525x | -- |
About Passage Bio Inc
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops P… Read more